中华放射肿瘤学杂志
中華放射腫瘤學雜誌
중화방사종류학잡지
Chinese Journal of Radiation Oncology
2015年
6期
619-622
,共4页
张江鹄%吴涛%王淑莲%金晶%刘跃平%王维虎%宋永文%余子豪%刘新帆%李晔雄
張江鵠%吳濤%王淑蓮%金晶%劉躍平%王維虎%宋永文%餘子豪%劉新帆%李曄雄
장강곡%오도%왕숙련%금정%류약평%왕유호%송영문%여자호%류신범%리엽웅
乳腺肿瘤/外科学%乳腺肿瘤/放射疗法%激素受体%HER-2基因%预后
乳腺腫瘤/外科學%乳腺腫瘤/放射療法%激素受體%HER-2基因%預後
유선종류/외과학%유선종류/방사요법%격소수체%HER-2기인%예후
Breast neoplasms/surgery%Breast neoplasms/radiotherapy%Hormone receptor%Human epidermal growth factor 2%Prognosis
目的：分析激素受体阴性、HER?2基因过表达局部晚期乳腺癌的局部复发风险和放疗作用。方法回顾分析1999—2011年间294例激素受体阴性、HER?2基因过表达局部晚期乳腺癌患者资料，其中239例接受改良根治术后辅助放疗，55例因各种原因未接受放疗，比较两组生存率和LRR率。 Kaplan?Meier法计算生存率和复发率，Logrank法检验和单因素预后分析，Cox回归模型多因素预后分析。结果5年样本数为162例。全组56例局部复发，5年无LRR率为79．7％，5年OS率为70．0％。放疗显著提高了5年LRRFS率（85．1％和56．0％，P＝0．000），但两组OS率相近（71．3％和64．2％，P＝0．441）。多因素分析显示辅助放疗是无 LRR 影响因素（ RR＝0．303，95％ CI 0．166～0．554，P＝0．000）。结论激素受体阴性、HER?2基因过表达局部晚期乳腺癌术后放疗显著降低了局部复发率。
目的：分析激素受體陰性、HER?2基因過錶達跼部晚期乳腺癌的跼部複髮風險和放療作用。方法迴顧分析1999—2011年間294例激素受體陰性、HER?2基因過錶達跼部晚期乳腺癌患者資料，其中239例接受改良根治術後輔助放療，55例因各種原因未接受放療，比較兩組生存率和LRR率。 Kaplan?Meier法計算生存率和複髮率，Logrank法檢驗和單因素預後分析，Cox迴歸模型多因素預後分析。結果5年樣本數為162例。全組56例跼部複髮，5年無LRR率為79．7％，5年OS率為70．0％。放療顯著提高瞭5年LRRFS率（85．1％和56．0％，P＝0．000），但兩組OS率相近（71．3％和64．2％，P＝0．441）。多因素分析顯示輔助放療是無 LRR 影響因素（ RR＝0．303，95％ CI 0．166～0．554，P＝0．000）。結論激素受體陰性、HER?2基因過錶達跼部晚期乳腺癌術後放療顯著降低瞭跼部複髮率。
목적：분석격소수체음성、HER?2기인과표체국부만기유선암적국부복발풍험화방료작용。방법회고분석1999—2011년간294례격소수체음성、HER?2기인과표체국부만기유선암환자자료，기중239례접수개량근치술후보조방료，55례인각충원인미접수방료，비교량조생존솔화LRR솔。 Kaplan?Meier법계산생존솔화복발솔，Logrank법검험화단인소예후분석，Cox회귀모형다인소예후분석。결과5년양본수위162례。전조56례국부복발，5년무LRR솔위79．7％，5년OS솔위70．0％。방료현저제고료5년LRRFS솔（85．1％화56．0％，P＝0．000），단량조OS솔상근（71．3％화64．2％，P＝0．441）。다인소분석현시보조방료시무 LRR 영향인소（ RR＝0．303，95％ CI 0．166～0．554，P＝0．000）。결론격소수체음성、HER?2기인과표체국부만기유선암술후방료현저강저료국부복발솔。
Objective To evaluate the risk of locoregional recurrence ( LRR ) and role of radiotherapy for patients with estrogen receptor?negative and human epidermal growth factor receptor 2?overexpressed ( Rec?/HER?2+) locally advanced breast cancer ( LABC ) . Methods A retrospective analysis was performed on the clinical data of 294 patients with Rec?/HER?2+LABC from 1999 to 2011. All patients were treated with modified radical mastectomy ( MRM ) . Of them, 239 patients received postmastectomy radiotherapy and 55 patients did not. Locoregional recurrence?free survival ( LRRFS) and overall survival ( OS) , as well as LRR, were compared between the two groups. The Kaplan?Meier method was used to estimate survival and recurrence rates, and the log?rank test was used for survival difference analysis and univariate prognostic analysis. Multivariate prognostic analysis was performed using the Cox regression model. Results The 5?year sample size was 162. Fifty?six patients developed LRR. The 5?year LRRFS and OS rates were 79. 7% and 70. 0%, respectively. Postmastectomy radiotherapy significantly increased the 5?year LRRFS rate ( 85. 1% vs. 56. 0%, P=0. 000) , but did not significantly increase the 5?year OS rate ( 71. 3% vs. 64. 2%, P= 0. 441 ) . Multivariate analysis indicated that postmastectomy radiotherapy was the only independent prognostic factor associated with increased LRRFS ( RR=0. 303, 95% CI:0. 166?0. 554, P=0. 000). Conclusions Patients with Rec?/HER?2+ LABC treated with MRM alone appear to be at a significantly increased risk of LRR compared with those treated with MRM followed by radiotherapy.
